SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Syndax Pharmaceuticals Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$13.09+0.19 (+1.47%)
Close on Oct 19, 2026
- Market cap
- $1.16B
- P/E (TTM)
- –
- Dividend yield
- –
Syndax Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $1.17B | $164.85M |
| Enterprise Value | $965.07M | $87.06M |
| PS Ratio | 4.63 | 3.60 |
| PB Ratio | 77.42 | 2.03 |
| P/TBV Ratio | 77.42 | 2.31 |
Enterprise value
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 3.83 | 2.43 |
Income (trailing twelve months)
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $252.25M | $57.94M |
| Operating Income | -$194.17M | -$21.44M |
| Net Income | -$220.77M | -$22.46M |
| EBITDA | -$194.17M | -$16.91M |
| EPS (Diluted) | -$2.51 | -$0.83 |
Margins
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -77.0% | -44.5% |
| Profit Margin | -87.5% | -39.2% |
| EBITDA Margin | -77.0% | -31.3% |
Returns
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -255.9% | -53.1% |
| Return on Assets (ROA) | -34.0% | -41.0% |
| Return on Capital Employed (ROCE) | -32.1% | -37.8% |
Growth
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 222.7% | 6.01% |
| Revenue Growth (5Y CAGR) | 157.7% | 6.42% |
Balance sheet
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $547.86M | $62.42M |
| Total Debt | $344.03M | $120.13M |
| Net Cash (Debt) | $203.83M | $15.68M |
| Net Cash Per Share | $2.28 | $0.66 |
| Equity (Book Value) | $15.10M | $48.79M |
| Book Value Per Share | $0.17 | $1.36 |
| Tangible Book Value | $15.10M | $23.06M |
| Working Capital | $575.36M | $75.77M |
Financial position
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 6.77 | 3.30 |
| Quick Ratio | 5.50 | 2.39 |
| Debt / Equity | 22.78 | 0.51 |
| Interest Coverage | -97085.50 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$220.64M | -$12.35M |
Efficiency
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.39 | 0.38 |
| Revenue Per Employee | $846.48K | $398.96K |
| Profits Per Employee | -$740.82K | -$703.34K |
| Employee Count | 298 | 74 |
Dividends and yields
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -18.9% | -22.7% |
Shares
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 89,297,100 | 58,179,650 |
| Shares Change (YoY) | 1.82% | 11.1% |
| Shares Change (QoQ) | 0.69% | 0.54% |
| Float | 87,660,900 | 49,173,100 |
| Shares Held by Insiders | 1.83% | 11.6% |
| Shares Held by Institutions | 121.1% | 59.4% |
Taxes
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $433.00K | $91.50K |
Scores
| Measure | Syndax Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -1.73 | -0.24 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Syndax Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.